Dr Brad Stanfield ✓
@BradStanfieldMD · New Zealand · joined 31 Jul 2020
Primary Care Physician (GP). Get your personalized health plan: https://t.co/zBENBBnBa6
135 523Followers
159Following
1 712Posts total
432KViews on collected posts
Postingan terbaru
Mencari postingan baru…
Topol is absolutely right.
Beware of the hype, team
11.1K views · 32 likes
· 0 reposts · 5 replies
Open on X →
@davidasinclair @JoinLifespan You keep proclaiming you have the 1st FDA approved clinical trial of age reversal. That's false.
The language by the FDA to @lifebiosciences was to clear a Phase 1 clinical trial testing ER-100 in people with certain optic-nerve diseases. Nothing ab
43.4K views · 257 likes
· 23 reposts · 12 replies
Open on X →
David Sinclair (@davidasinclair) on the @joerogan podcast said that GLP-1s (such as Ozempic) have double sudden blindness rates
It's difficult not to get irritated with this poor science communication.
That alarm comes from 37 patients at one eye clinic. NAION is still about 1
24.8K views · 285 likes
· 34 reposts · 26 replies
Open on X →
6:14
Disappointing clinical study results continue to pile up for NR and NMN supplements
In a 12-week double-blind, randomized, placebo-controlled pilot study of NR, there were no improvements in cognitive function (primary outcome), total CBF, or blood pressure (secondary outcomes)
11.4K views · 80 likes
· 5 reposts · 9 replies
Open on X →
@BradStanfieldMD Excellent! It is so important to publish negative studies with the same zest as positive ones. Great work with this one!
5.1K views · 154 likes
· 6 reposts · 3 replies
Open on X →
The bottom line:
Exercise remains the single best intervention for preserving function in older adults. Full stop.
I've always advocated that Rapamycin should NOT be used outside of FDA-approved indications and clinical trials
Paper: https://t.co/c3B4Oq0fNz
11.8K views · 159 likes
· 20 reposts · 13 replies
Open on X →
I crowdfunded this trial with the help of @LifespanNews and @vita_dao. No pharma money. No conflicts with the drug.
I genuinely hoped this would work. But science doesn't care about our hopes, and negative results matter just as much.
6.4K views · 147 likes
· 4 reposts · 7 replies
Open on X →
Important caveats:
1) This was 13 weeks. Longer trials may show different results
2) Only one dose/schedule tested. Less frequent dosing (every 3-6 weeks) might allow full drug clearance between exercise sessions
3) 40 participants. Exploratory, not definitive
4.6K views · 46 likes
· 2 reposts · 1 replies
Open on X →
Why didn't the cycling hypothesis work?
Leading theory is a pharmacokinetic problem.
Rapamycin's half-life is ~62 hours. Even dosing it the day after exercise, active drug levels persisted into the next training sessions, partially blocking mTOR when muscles needed it most.
4.3K views · 46 likes
· 1 reposts · 3 replies
Open on X →
This parallels what we see with metformin. Two studies have shown metformin (also an indirect mTOR inhibitor) blunts exercise adaptations in older adults.
4.3K views · 58 likes
· 5 reposts · 2 replies
Open on X →
In the per-protocol analysis (people who actually followed the programme), the placebo group gained ~3.4 more chair-stand reps than the Rapamycin group.
p = 0.007. Cohen's d = -0.90. That's a large negative effect.
4.8K views · 42 likes
· 0 reposts · 1 replies
Open on X →
Every muscle performance secondary outcome pointed the same direction:
- 6-min walk distance: favoured placebo
- Grip strength: favoured placebo
4.6K views · 39 likes
· 1 reposts · 1 replies
Open on X →
Safety: both groups had similar rates of people reporting side effects (85% each).
But the Rapamycin group had far more total events: 99 vs 63.
One participant was hospitalised with pneumonia after a single Rapamycin dose.
4.7K views · 37 likes
· 1 reposts · 1 replies
Open on X →
We timed the rapamycin dose 24 hours AFTER the last exercise session each week, specifically to avoid blocking the anabolic window.
Both groups improved. But the placebo group improved more.
5.1K views · 45 likes
· 0 reposts · 3 replies
Open on X →
We ran the first double-blind, placebo-controlled trial combining weekly Rapamycin (Sirolimus) 6mg with exercise in older adults.
40 sedentary people aged 65-85. Both groups did the same 13-week at-home exercise programme. Half got Rapamycin, half got Placebo.
6.8K views · 60 likes
· 3 reposts · 4 replies
Open on X →
The idea: the "cycling hypothesis."
Exercise activates mTOR → muscle growth. Rapamycin inhibits mTOR → autophagy and cellular cleanup.
Alternate the two and you get the best of both worlds. At least, that was the theory.
5.9K views · 46 likes
· 0 reposts · 3 replies
Open on X →
Our Rapamycin & Exercise clinical trial has just been published!
The topline result?
Rapamycin didn't help. Instead, it may have made things worse.
Here's what we found 🧵
https://t.co/vpy9bPrGDJ https://t.co/GC6974lExP
266.8K views · 879 likes
· 154 reposts · 96 replies
Open on X →
Dibandingkan akun berukuran sama
5 postingan dari 90 hari terakhir, dibandingkan dengan rentang 100K–1M pengikut. tampil luas, tetapi sedikit penonton yang merespons.
Median tayangan11 397akun ini5 983median untuk 100K–1M
Jangkauan, %8.41%akun ini1.49%median untuk 100K–1M
Interaksi, %0.69%akun ini0.93%median untuk 100K–1M
| Metrik | Akun ini | Median untuk 100K–1M | Rasio |
|---|---|---|---|
| Median tayangan per postingan | 11 397 | 5 983 | 1.90× |
| Jangkauan (tayangan ÷ pengikut) | 8.41% | 1.49% | 5.64× |
| Tingkat interaksi | 0.69% | 0.93% | 0.74× |
Akun lain pada rentang ini → Bandingkan dengan akun lain → Bagaimana tolok ukur ini disusun →
Growth & engagement
How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.
Views per post
4.7K16 Apr
4.6K
4.8K
4.3K
4.3K
4.6K
6.4K
11.8K
5.1K
11.4K24 Jul
24.8K20 Aug
43.4K25 Aug
11.1K26 Aug
6.1K
Last 14 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.
Engagement rate per post
0.86%16 Apr
0.91%
0.90%
1.54%
1.18%
1.08%
2.48%
1.65%
3.17%
0.85%24 Jul
1.40%20 Aug
0.69%25 Aug
0.33%26 Aug
0.49%
Reactions — likes, reposts, replies and quotes — divided by views. Median for 100K–1M accounts is 0.93%.
What the audience does
Likes69.8%2 440 in total
Reposts7.4%259 in total
Replies5.5%191 in total
Quotes2.5%89 in total
Bookmarks14.8%519 in total
Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.
The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.
Akun serupa
Binkasem | بن قاسم ✓
@1binkasem
271K followers
· 1.5K posts
魔入りました！ 入間くん【公式】 ✓
@wc_mairuma
271K followers
· 3.8K posts
STRAY KIDS LATAM PROJECT 🥤 ✓
@skzlatamproject
271K followers
· 103.7K posts
MrsPJHaverstock ✓
@MrsPJHaverstock
271K followers
· 11K posts
Congreso
@Congreso_Es
271K followers
· 44.4K posts
24sata
@24sata_HR
271K followers
· 249.5K posts
찌 G 跻 じ MBA, CFA, FRM, CFP, NGMI, HFSP, HENTAI 🛡️ ✓
@DegenSpartan
271K followers
· 966 posts
Autocar India
@autocarindiamag
271K followers
· 79.9K posts